Showing 4781-4790 of 9153 results for "".
- Phase 2b Study: Arcutis' Roflumilast Cream Shows Sustained Efficacy in Adults with Chronic Plaque Psoriasishttps://practicaldermatology.com/news/pgase-2b-study-arcutis-roflumilast-cream-shows-sustained-efficacy-in-adults-with-chronic-plaque-psoriasis/2461513/Arcutis' roflumilast cream showed sustained efficacy with clearance for median of 10 Months in adults with chronic plaque psoriasis, according to an open label Phase 2 long-term safety study presented at the Winter Clinical dermatology meeting. Roflumilast cream
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T
- La Roche Posay Celebrates Second Annual National HA Day on Jan. 21, 2023https://practicaldermatology.com/news/la-roche-posay-celebrates-second-annual-national-ha-day-on-jan-21-2023/2461510/La Roche-Posay is ringing in its second annual National Hyaluronic Acid Day on January 21st. To celebrate National Hyaluronic Acid Day, the brand is offering 20% off on orders of $65 or more on
- Sun Pharma Launches New AH-ha! It’s Acne Hormones Campaignhttps://practicaldermatology.com/news/sun-pharma-launches-new-ah-ha-its-acne-hormones-campaign/2461509/Sun Pharmaceutical Industries, Inc, is launching "AH-ha! It's Acne Hormones," an awareness campaign featuring Sandra Lee, MD (AKA TLC's "Dr. Pimple Popper"). The campaign is designed to spotlight hormones as
- Simple Laser Treatments May Help Prevent Nonmelanoma Skin Cancerhttps://practicaldermatology.com/news/simple-laser-treatments-may-help-prevent-nonmelanoma-skin-cancer/2461508/Nonablative fractional lasers treatments may help prevent basal cell carcinoma and squamous cell carcinoma, a new study suggests. Nonablative fractional lasers (NAFL) are currently used to treat scars, sun-damaged skin, age spots, and more; however, their effectiveness for pre
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced
- ASA Earns Candid's Platinum Seal of Transparencyhttps://practicaldermatology.com/news/asa-earns-candids-platinum-seal-of-transparency/2461505/The American Skin Association (ASA) recieved Candid's Platinum Seal of Transparency, previously recognized as GuideStar's Platinum Seal of Transparency. Candid collects nonprofit data, and this designation demonstrates that ASA is an organization focused on measuring progr
- Hydrafacial Improves Acne Skin Concerns: Studyhttps://practicaldermatology.com/news/hydrafacial-improves-acne-skin-concerns-study/2461501/Hydrafacial improves acne skin concerns, according to a new study published in the Journal of Clinical and Aesthetic Dermatology (JCAD). Fully 100 percent of study participants reported clearer, less inflamed skin after a series of treatments with Hydrafacial’s pate
- New Guidance Issued on Treating Metastatic Melanoma During COVID-19https://practicaldermatology.com/news/new-guidance-issued-on-treating-metastatic-melanoma-during-covid-19/2461497/Metastatic melanoma patients taking systemic therapy should stay on treatment whenever possible, even during Covid-19 pandemic. This is the main takeaway from new research paper in Oncotarget's
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no